Claims

1. Use of albendazole as an active ingredient in the manufacture of a medicament for the treatment of Beko disease or a myxosporean disease in a marine fish wherein the medicament is to be administered to a marine fish at a daily dose of 10 to 40 mg/kg body weight, wherein a parasite causing the Beko disease is a microsporidian parasite belonging to the genus *Microsporidium*, and a parasite causing the myxosporean disease is a myxosporidian parasite belonging to the genus *Kudoa*.

2. The use according to Claim 1, wherein the active ingredient is to be orally administered to the marine fish in a dose of 10 to 30 mg/kg body weight per day.

3. The use according to Claim 1 or 2, for the treatment of Beko disease and myxosporean disease.

4. The use according to any of claims 1 to 3, wherein the marine fish is a fish of the order *Perciformes*, the order *Pleuronectiformes* or the order *Tetraodontiformes*.

5. The use according to claim 4, wherein the fish of the order *Perciformes* is a fish belonging to the genus *Seriola*, the family *Sparidae*, or the genus *Thunnus*; wherein the fish of the order *Pleuronectiformes* is a fish belonging to the family *Paralichthyidae*; or wherein the fish belonging to the order *Tetraodontiformes* is a fish belonging to the family *Tetraodontidae*.

6. The use according to claim 5, wherein the fish belonging to the genus *Seriola* is any of yellowtail (*Seriola quinqueradiata*), greater amberjack (*Seriola dumerili*), gold striped amberjack (*Seriola lalandi*), Almaco jack (*Seriola rivoliana*), Guinean amberjack (*Seriola*

carpenteri), lesser amberjack (*Seriola fasciata*), samsonfish (*Seriola hippos*), fortune jack (*Seriola peruana*), and banded rudderfish (*Seriola zonata*); wherein the fish belonging to the family *Sparidae* is any of Okinawa seabream (*Acanthopagrus sivicolus*), king soldier bream (*Argyrops bleekeri* Oshima), yellowback seabream (*Dentex tumifrons*), crimson seabream (*Evynnis tumifrons*), red seabream (*Pagrus major*), blackhead seabream (*Acanthopagrus schlegelii*), and goldlined seabream (*Rhabdosargus sarba*, *Sparus sarba*); wherein the fish belonging to the genus *Thunnus* is any of Pacific bluefin tuna (*Thunnus orientalis*), Atlantic bluefin tuna (*Thunnus thynnus*), southern bluefin tuna (*Thunnus maccoyii*), bigeye tuna (*Thunnus obesus*), albacore tuna (*Thunnus alalunga*), yellowfin tuna (*Thunnus albacares*), longtail tuna (*Thunnus tonggol*), and blackfin tuna (*Thunnus atlanticus*); wherein the fish belonging to the family *Paralichthyidae* is any of olive flounder (*Paralichthys olivaceus*), California flounder (*Paralichthys californicus*), summer flounder (*Paralichthys dentatus*), fivespot flounder (*Pseudorhombus pentophthalmus*), cinnamon flounder (*Pseudorhombus cinnamoneus*), ocellated flounder (*Pseudorhombus dupliciocellatus*), largetooth flounder (*Pseudorhombus arsius*), and pygmy whiff (*Tarphops oligolepis*); or wherein the fish belonging to the family *Tetraodontidae* is tiger puffer (*Takifugu rubripes*) or purple puffer (*Takifugu porphyreus*).

7. The use according to any of claims 1 to 6, wherein the duration of administration of the active ingredient is 1 to 20 days.

8. The use according to any of claims 1 to 7, wherein the duration of administration of the active ingredient is 3 to 10 days.

9. The use according to any of claims 1 to 8, wherein a duration of 10 to 17 days in which the active ingredient is not administered is set after the administration of the active ingredient.

10. The use according to any of claims 1 to 9, wherein the administration starts 9 to 23 days

after a juvenile fish is transferred from a sea cage.